It's weird how different graphics cards are from pharmaceuticals. Both have big startup and research costs, but GPUs are basically obsolete in a couple years, they run the supply out and constantly plan to move to the next model. Pharma you can do that, or build a portfolio and collect rents for a while.

It's weird that patent durations are one sized fits all, even though how long you can capture value is completely dependent on the industry.